Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaZ02 pazopanib study in advanced clear-cell renal cell carcinoma with ECOG 2
ISRCTN38957238Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Feb 2013
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in clear cell renal cell carcinoma (ccRCC), sponsored by University of Birmingham. Primary endpoints: Tolerability at 6 months and Efficacy at 6 months. Started Feb 2013; status: completed.
02
Drugs
pazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ISRCTN38957238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38957238.